메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

PR Newswire Launches Amplify: AI Platform to Accelerate Modern PR and Communications Capabilities

[ 메디채널 황정호 기자 ] A new platform gives communicators the tools to transform a single press release into a full-scale campaign, ensuring their message breaks through to global audiences and AI alike. NEW YORK, Sept. 22, 2025 -- In a world where consolidating newsrooms and AI-driven search are redefining how stories are discovered, the press release is increasingly the bedrock of credible, trusted, brand communication. When used as the foundation for a robust multichannel communications strategy it accelerates message reach and effectiveness, while ensuring an authenticated message direc
- 황정호 기자
- 2025-09-22 21:15
Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities SEOUL, South Korea, Sept. 22, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in t
- 김갑성 기자
- 2025-09-22 21:00
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets

[ 메디채널 김갑성 기자 ] Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 -- Galux, a South Korea–based biotech company pioneering AI-driven protein therapeutics design, today announced new results that further validate its de novo antibody design platform, GaluxDesign. The findings showcase the platform's ability to generate novel antibodies that meet precise st
- 김갑성 기자
- 2025-09-22 21:00
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

BOSTON, Sept. 22, 2025 -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway. The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network tha
- 김갑성 기자
- 2025-09-22 20:00
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

BEIJING, Sept. 22, 2025 -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, September 22, 2025, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq"). On the same day, the Company's ordinary shares and wa
- 황정호 기자
- 2025-09-22 20:00
CHICAGO RIVER SWIM MAKES HISTORIC RETURN AFTER NEARLY A CENTURY

Raises $150,000 to support ALS research and youth swim education CHICAGO, Sept. 22, 2025 -- The Chicago River Swim returned on Sunday, September 21, for the first time in 98 years, marking a historic milestone for the city and drawing thousands of swimmers, civic leaders and spectators to the heart of downtown. The event, produced by the nonprofit A Long Swim, celebrated decades of environmental progress while raising $150,000 for ALS research at the Ozdinler Lab of Northwestern's Feinberg School of Medicine and swim-safety education programs at the Salvation Arm
- 황정호 기자
- 2025-09-22 19:10
Biotic innovation tackles iron deficiency in women - now recognized across three continents

STOCKHOLM, Sept. 22, 2025 -- A health solution designed to improve iron absorption in women has garnered international acclaim, earning top awards in Europe, North America, and now Asia. This triple recognition in 2025 highlights a growing global awareness of the need for more effective, better-tolerated iron supplementation. Developed by biotics solutions company Probi, the concept includes the clinically studied probiotic strain, Lactiplantibacillus plantarum 299v (LP299V®). When combined with iron, LP299V® increases iron absorption and reduces gastrointestinal side
- 김갑성 기자
- 2025-09-22 18:23
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First Dedicated Cancer Centre for Women

NEW DELHI, Sept. 22, 2025 -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch of Apollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister of Delhi, Smt. Rekha Gupta, in the presence of Dr. Prathap C Reddy, Founder-Chairman, Apollo Hospitals Group; Ms. Bansuri Swaraj, Member of Parliament, New Delhi; Shri Neeraj Basoya, Member of the Legislative Assembly; Ms. Preetha Reddy, Executive Vice Chairperson, AHEL; and Mr. Harshad Reddy, Director, Group Oncology, AH
- 김갑성 기자
- 2025-09-22 15:43
PHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer Screening

GUANG'AN, China, Sept. 22, 2025 -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an, Sichuan Province, China. This study is led by Peking University Shenzhen Hospital, with participation from West China Guang'an Hospital of Sichuan University and technical and diagnostic support by PHASE Scientific. The study applies PHASE Scientific's proprietary PHASiFY™ urine-based DNA concent
- 김갑성 기자
- 2025-09-22 15:39
Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer

HONG KONG, Sept. 22, 2025 -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab (PD-1/VEGF bispecific antibody), for treating locally advanced or metastatic pancreatic cancer in patients who have failed up to two prior lines of systemic therapy. AK130 is the world's first and only TIGIT/TGF-β bifunctional antibody fusion protein in registrational clinical development. The initiation of
- 김갑성 기자
- 2025-09-22 14:51

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분